ABSTRACT
Pharmacogenomic markers from germline or tumour DNA can provide useful information pertaining to response or toxicity from chemotherapy drugs. The US Food and Drug Administration (FDA) has begun to approve clinical tests for pharmacogenomics markers and also to approve changes to package inserts to reflect pharmacogenomics knowledge. This chapter discusses the current understanding of cancer pharmacogenomics, with reference to commonly used anti-cancer agents such as mercaptopurine, tamoxifen, irinotecan and 5-fluorouracil. Data for markers in TPMT, DPYD, CYP2D6, and TYMS is described.
